Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of intravenous almitrine in reducing the need for mechanical ventilation in COVID-19-related hypoxemic acute respiratory failure
2020-001909-22Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia and Acute hypoxaemic respiratory failure (AHRF) comparing Intravenous almitrine with Placebo (2 arms). Primary endpoint: Endotracheal intubation within 7 days. Started Apr 2020; status: completed.
02
Drugs
almitrine
03
Conditions
coronavirus pneumoniaAcute hypoxaemic respiratory failure (AHRF)
Beyond the preview
Go deeper on 2020-001909-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001909-22.